| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michal Hrdlicka, Iva Dudov. Risperidone in adolescent schizophrenic psychoses: A retrospective study. International journal of psychiatry in clinical practice. vol 11. issue 4. 2014-06-20. PMID:24940726. |
the aim of the study was to assess the therapeutic effect and tolerability of risperidone in patients with early-onset schizophrenia and other related psychotic disorders. |
2014-06-20 |
2023-08-13 |
human |
| Tamás Treuer, Martin Anders, Istvan Bitter, Gheorghe Dobre, Jan Pecenak, Yulia Dyachkova, Gavan Harrison, John O'Mahone. Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO). International journal of psychiatry in clinical practice. vol 10. issue 2. 2014-06-20. PMID:24940957. |
patients initially prescribed olanzapine and risperidone experienced significantly greater improvements in a broad range of schizophrenia symptom domains compared with patients prescribed typicals. |
2014-06-20 |
2023-08-13 |
Not clear |
| Beat Nick, Roland Vauth, Daniel Braendle, Anita Riecher-Rössler, The Swiss StoRMi Investigators Grou. Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable. International journal of psychiatry in clinical practice. vol 10. issue 3. 2014-06-20. PMID:24941055. |
to investigate antipsychotic efficacy and tolerability of risperidone long-acting injectable (rlai) in swiss patients with schizophrenia or other psychotic disorders, changed directly from their previous antipsychotic medication. |
2014-06-20 |
2023-08-13 |
Not clear |
| Pierre-Michel Llorca, Jean-Pierre Kahn, Véronique Moreau-Mallet, Philippe Bouhours, The French StoRMi Investigators Grou. Symptom control, functioning, and hospitalization status in French patients changed from oral atypical antipsychotics to risperidone long-acting injectable. International journal of psychiatry in clinical practice. vol 10. issue 4. 2014-06-20. PMID:24941147. |
to investigate efficacy and tolerability of risperidone long-acting injectable (rlai) in french patients with schizophrenia or other psychotic disorders, who were all switching from previous treatment with oral atypical antipsychotics. |
2014-06-20 |
2023-08-13 |
Not clear |
| Janusz K Rybakowski, Marek Jarem. Long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: An international multicenter study. International journal of psychiatry in clinical practice. vol 8. issue 3. 2014-06-20. PMID:24941204. |
long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: an international multicenter study. |
2014-06-20 |
2023-08-13 |
Not clear |
| Janusz K Rybakowski, Marek Jarem. Long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: An international multicenter study. International journal of psychiatry in clinical practice. vol 8. issue 3. 2014-06-20. PMID:24941204. |
objective the aim of this open multicenter international study was an assessment of the efficacy and tolerability of risperidone administered for 12 months in patients with early schizophrenia. |
2014-06-20 |
2023-08-13 |
Not clear |
| Janusz K Rybakowski, Marek Jarem. Long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: An international multicenter study. International journal of psychiatry in clinical practice. vol 8. issue 3. 2014-06-20. PMID:24941204. |
conclusion the results suggest that, in a substantial proportion of patients with early schizophrenia, risperidone can be successfully used for initiation of pharmacological treatment of schizophrenia and then be continued on the long-term basis. |
2014-06-20 |
2023-08-13 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. |
2014-06-17 |
2023-08-13 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
the aims of this 13-week study were to examine the efficacy and safety of amisulpride, and effects on cognitive function in patients with schizophrenia after they switched from risperidone. |
2014-06-17 |
2023-08-13 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
twenty-three patients with schizophrenia whose antipsychotic was switched from risperidone to amisulpride were recruited. |
2014-06-17 |
2023-08-13 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
switching antipsychotic from risperidone to amisulpride in schizophrenia might have significantly improved not only the efficacy, but also various domains of cognitive function. |
2014-06-17 |
2023-08-13 |
Not clear |
| Phil Lee, Chul Eung Kim, Chang Yoon Kim, Wei-Wen Lin, Hussain Habil, Yulia Dyachkova, Margaret Mcbride, Martin Dossenbac. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931661. |
long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the intercontinental schizophrenia outpatient health outcomes (ic-soho) study. |
2014-06-17 |
2023-08-13 |
Not clear |
| Phil Lee, Chul Eung Kim, Chang Yoon Kim, Wei-Wen Lin, Hussain Habil, Yulia Dyachkova, Margaret Mcbride, Martin Dossenbac. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931661. |
to compare the effectiveness of olanzapine, risperidone, quetiapine, or haloperidol monotherapy in patients with schizophrenia who were treated in routine clinical practice settings for a period of 2 years. |
2014-06-17 |
2023-08-13 |
Not clear |
| Phil Lee, Chul Eung Kim, Chang Yoon Kim, Wei-Wen Lin, Hussain Habil, Yulia Dyachkova, Margaret Mcbride, Martin Dossenbac. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931661. |
outpatients with schizophrenia who entered this 3-year, prospective, observational study were classified according to their initially prescribed antipsychotic monotherapy: olanzapine (n=3222), risperidone (n=1116), quetiapine (n=189), or haloperidol (n=256). |
2014-06-17 |
2023-08-13 |
Not clear |
| A Hal. Sertindole: a clinical efficacy profile. International journal of psychiatry in clinical practice. vol 6. issue 1. 2014-06-17. PMID:24931885. |
it is at least as efficacious as haloperidol and risperidone in treating the overall and positive symptoms of schizophrenia and has been shown to have advantages over these two drugs with respect to the treatment of the negative symptoms of schizophrenia. |
2014-06-17 |
2023-08-13 |
Not clear |
| J K Borkowsk. The effect of treatment with risperidone, olanzapine or phenothiazines on cognitive functions in patients with schizophrenia. International journal of psychiatry in clinical practice. vol 5. issue 4. 2014-06-14. PMID:24921692. |
the effect of treatment with risperidone, olanzapine or phenothiazines on cognitive functions in patients with schizophrenia. |
2014-06-14 |
2023-08-13 |
Not clear |
| Beata Konarzewska, Beata Galińska-Skok, Napoleon Waszkiewicz, Joanna Łazarczyk-Kirejczyk, Aleksandra Malus, Katarzyna Simonienko, Agata Szul. Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone. Neuro endocrinology letters. vol 35. issue 1. 2014-06-12. PMID:24625910. |
association between serum testosterone levels, body mass index (bmi) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone. |
2014-06-12 |
2023-08-12 |
Not clear |
| Beata Konarzewska, Beata Galińska-Skok, Napoleon Waszkiewicz, Joanna Łazarczyk-Kirejczyk, Aleksandra Malus, Katarzyna Simonienko, Agata Szul. Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone. Neuro endocrinology letters. vol 35. issue 1. 2014-06-12. PMID:24625910. |
the main purpose of the present study was to examine the correlations between testosterone, estradiol bmi, and insulin in male patients diagnosed with schizophrenia and treated with olanzapine or risperidone. |
2014-06-12 |
2023-08-12 |
Not clear |
| Chang Yoon Kim, Seockhoon Chung, Bong-Jin Hahm, Kyung Sue Hong, Jin-Sang Yoon, Young-Hoon Kim, Won-Myong Bahk, Sang-Yeol Lee, Yanghyun Lee, In-Won Chung, Chan-Hyung Ki. Effectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychotics. International journal of psychiatry in clinical practice. vol 13. issue 3. 2014-06-12. PMID:24916820. |
the aim of this non-randomized, single-arm, multi-center, 9-month extension study was to evaluate the maintained efficacy and tolerability of long-acting risperidone injection when we switched to it from previous oral antipsychotics in symptomatically stable patients with schizophrenia or other psychotic disorders. |
2014-06-12 |
2023-08-13 |
Not clear |
| Chang Yoon Kim, Seockhoon Chung, Bong-Jin Hahm, Kyung Sue Hong, Jin-Sang Yoon, Young-Hoon Kim, Won-Myong Bahk, Sang-Yeol Lee, Yanghyun Lee, In-Won Chung, Chan-Hyung Ki. Effectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychotics. International journal of psychiatry in clinical practice. vol 13. issue 3. 2014-06-12. PMID:24916820. |
switching to long-acting risperidone injection from oral antipsychotics was a safe and well-tolerated strategy for maintaining clinical stability in symptomatically stable patients with schizophrenia. |
2014-06-12 |
2023-08-13 |
Not clear |